Immix Biopharma has announced that it will present updated clinical data relating to its lead CAR-T asset, NXC-201, in relapsed/refractory amyloid light chain amyloidosis (r/r ALA) at the upcoming American Society of Hematology 2025 Annual Meeting (ASH 2025; 6–9 December). The data will come from the ongoing US-based NEXICART-2 trial, which is a multi-site, Phase I/II clinical study with a registrational design. The most recent clinical update corresponded to 10 out of the expected 40 patients, and hence, the update at ASH 2025 represents an important upcoming catalyst.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment